

CVD escalation therapy for secondary prevention (update) committee meeting 5

Date: 31/07/2023

Location: Virtual via Zoom

Minutes: Final

Committee members present:	
Nigel Beckett	
Chris Clark	
Hugh Gallagher	
Aroon Hingorani (Co-opted member)	
Satwinder Kaur	
Joseph Mills (Chair)	
Riyaz Patel (Topic adviser)	
David Preiss	
Ruth Price	
Chakravarthi Rajkumar (Co-opted member)	
Eduard Shantsila	
Wayne Sunman	

In attendance:		
Catrina Charlton	Guideline Commissioning Manager	
Alfredo Mariani	Technical Analyst (Economics)	
Edgar Masanga	Resource Impact Lead	
Joanna Perkin	Medical Editor	
Eric Power	Programme Director, Centre for Guidelines	
Eleanor Samarasekera	Senior Systematic Reviewer	
Sharon Swain	Associate Director, GDT NGC	
Amelia Unsworth	Senior Project Manager	

4.0.03 DOC Cmte minutes

NICE observers:

Charlotte Fairclough	Technical Adviser, Quality standards & indicators team
----------------------	--

Apologies:

Parijat De	Co-opted member
Paul Leeson	Committee member
Colin Wilkinson	Lay member
Lina Gulhane	Head of Information Specialists, GDT NGC
David Wonderling	Head of Health Economics

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 5th meeting on CVD escalation therapy for secondary prevention.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: discussion of the feedback received from stakeholder engagement workshops, evidence summary from the TA on bempedoic acid and CLEAR outcomes trial, changes to the health economic model and draft recommendations.

2. Confirmation of matters under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:

- lipid-lowering therapies for escalation of therapy for secondary prevention for people with CVD.

The Chair asked everyone to verbally declare any interests in addition to those previously declared.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Eduard Shantsila	Senior Clinical Lecturer in Primary Care and Mental Health,	Attended the European Society of Cardiology (ESC) Plenary Meeting on "THE FUTURE OF CLINICAL TRIALS:	Direct financial	Non-specific No action needed other than

4.0.03 DOC Cmte minutes

	University of Liverpool	<p>TOWARDS DIVERSITY on how to support the inclusion of various underrepresented groups (mainly women and ethnic minority groups) in research overall and particularly in clinical trials. The organisers (ESC) covered the costs of the hotel for two nights and contributed to the travel costs.</p> <p>In the ESC, I represent the Primary Care and Risk Factor Management Section (secretary of the section) of the European Association of Preventative Cardiology, which is part of the ESC, 31.7.23.</p>		<p>process of open declaration</p> <p>Reasonable attendance costs</p>
Hugh Gallagher	Consultant Nephrologist, Epsom and St Helier NHS Trust	Attended an AstraZeneca short talk on SGLT2i at a renal meeting, reasonable subsistence was provided, 31.7.23.	Direct non-financial professional and personal	<p>Non-specific</p> <p>No action needed other than process of open declaration</p>
Ruth Price	Advanced Clinical Pharmacist for Cardiovascular Services, Leeds Teaching Hospitals NHS Trust	Secondment to primary care for heart failure therapy roll out in Leeds finished in June 2023 and has returned to substantive role of Advanced Clinical Pharmacist for Cardiovascular Services at Leeds Teaching Hospitals NHS Trust, 31.7.23.	Direct financial	<p>Non-specific</p> <p>No action needed other than process of open declaration - salaried employment in the NHS</p>
Wayne Sunman	Consultant Stroke Physician, City Hospital	Attended a meal funded by Novartis. Presentations on the regulatory position of	Direct financial	<p>Specific</p> <p>No action needed other than</p>

4.0.03 DOC Cmte minutes

	Campus of Nottingham University Hospitals NHS Trust	inclisiran and the rationale, practicalities and economics of administering it, by a stroke physician, a cardiologist and a clinical chemist working at my Trust, 31.7.23.		process of open declaration Reasonable attendance costs
<p>The Chair and a senior member of the developer team did not consider that these new interests posed a conflict with the topic under consideration and therefore no action was required</p> <p>The Chair and a senior member of the Developer's team reviewed the declarations of interest register for interests previously declared and noted that none posed a conflict with the matters under discussion, therefore no further action was required.</p>				
3. Committee membership update				
The Committee was given an update on the committee membership.				
4. Feedback from stakeholder engagement workshops				
The Committee was given a summary of the feedback received from stakeholder engagement workshops.				
5. Existing guideline recommendations on statin intolerance				
The Committee was reminded of the current recommendations in CG181 on statin intolerance.				
6. Summary of evidence on bempedoic acid				
The Committee was given a presentation on the summary of evidence on bempedoic acid.				
7. Update on CPRD analysis and health economic model				
The Committee was given a presentation on the update to the CPRD data analysis and changes to the health economic model.				
8. Draft recommendations				
The Committee discussed the draft recommendations.				
9. Timeline and next steps				
The Committee was given an update on the timeline and next steps.				

4.0.03 DOC Cmte minutes

10. Any other business
None

Date of next meeting: 23/10/23

Location of next meeting: Virtual via Zoom